Polymicrobial infections and antibiotic treatment patterns for cystic fibrosis pulmonary exacerbations

被引:3
作者
V. Faino, Anna [1 ,4 ]
Hoffman, Lucas R. [2 ]
Gibson, Ronald L. [2 ]
Kronman, Matthew P. [3 ]
Nichols, David P. [2 ]
Rosenfeld, Margaret [2 ]
Cogen, Jonathan D. [2 ]
机构
[1] Seattle Childrens Res Inst, Core Biostat Epidemiol & Analyt Res, Seattle, WA USA
[2] Univ Washington, Dept Pediat, Div Pulm & Sleep Med, Seattle, WA USA
[3] Univ Washington, Seattle Childrens Hosp, Div Infect Dis, Dept Pediat, Seattle, WA USA
[4] Seattle Childrens Res Inst, 1920 Terry Ave,Mail Stop CURE 4, Seattle, WA 98101 USA
关键词
OROPHARYNGEAL CULTURES; THERAPY; INFANTS;
D O I
10.1016/j.jcf.2023.02.001
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: No data exist to guide antibiotic selection among people with CF (PwCF) with respiratory cultures positive for multiple CF-related bacteria (polymicrobial infections). This study aimed to describe the number of polymicrobial in-hospital treated pulmonary exacerbations (PEx), to determine the proportion of polymicrobial PEx where antibiotics were prescribed with activity against all bacteria detected (termed complete antibiotic coverage), and to determine clinical and demographic factors associated with complete antibiotic coverage.Methods: Retrospective cohort study using the CF Foundation Patient Registry-Pediatric Health Information System dataset. Children aged 1-21 years with an in-hospital treated PEx from 2006 to 2019 were eligible for inclusion. Bacterial culture positivity was based on any positive respiratory culture in the 12 months prior to a study PEx. Results: A total of 4,923 children contributed 27,669 total PEx of which 20,214 were polymicrobial; of these, 68% of PEx had complete antibiotic coverage. In regression modeling, a prior PEx with complete antibiotic coverage for MRSA was associated with a higher likelihood of having complete antibiotic coverage at a subsequent study PEx (OR (95% CI) 3.48 (2.50, 4.83)).Conclusions: The majority of children with CF hospitalized for polymicrobial PEx were prescribed complete antibiotic coverage. Prior PEx treatment with complete antibiotic coverage predicted complete antibiotic coverage at a future PEx for all bacteria studied. Studies are needed comparing outcomes of polymicrobial PEx treated with different antibiotic coverages to optimize PEx antibiotic selection.(c) 2023 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:630 / 635
页数:6
相关论文
共 50 条
  • [1] Impact of antibiotic treatment for pulmonary exacerbations on bacterial diversity in cystic fibrosis
    Daniels, T. W. V.
    Rogers, G. B.
    Stressmann, F. A.
    van der Gast, C. J.
    Bruce, K. D.
    Jones, G. R.
    Connett, G. J.
    Legg, J. P.
    Carroll, M. P.
    JOURNAL OF CYSTIC FIBROSIS, 2013, 12 (01) : 22 - 28
  • [2] Treatment Setting and Outcomes of Cystic Fibrosis Pulmonary Exacerbations
    Schechter, Michael S.
    VanDevanter, Donald R.
    Pasta, David J.
    Short, Sarah A.
    Morgan, Wayne J.
    Konstan, Michael W.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2018, 15 (02) : 225 - 233
  • [3] Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations
    VanDevanter, Donald R.
    O'Riordan, Mary A.
    Blumer, Jeffrey L.
    Konstan, Michael W.
    RESPIRATORY RESEARCH, 2010, 11
  • [4] Impact of viral respiratory infections on pulmonary exacerbations in children with cystic fibrosis
    Gonzalez-Rosales, Noel
    Kasi, Ajay S. S.
    McCracken, Courtney E. E.
    Silva, George L. L.
    Starks, Miah
    Stecenko, Arlene
    Guglani, Lokesh
    PEDIATRIC PULMONOLOGY, 2023, 58 (03) : 871 - 877
  • [5] Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients
    Waters, Valerie J.
    Stanojevic, Sanja
    Sonneveld, Nicole
    Klingel, Michelle
    Grasemann, Haitmut
    Yau, Yvonne C. W.
    Tullis, Elizabeth
    Wilcox, Pearce
    Freitag, Andreas
    Chilvers, Mark
    Ratjen, Felix A.
    JOURNAL OF CYSTIC FIBROSIS, 2015, 14 (06) : 755 - 762
  • [6] Characterization of Inpatient Cystic Fibrosis Pulmonary Exacerbations
    Cogen, Jonathan D.
    Oron, Assaf P.
    Gibson, Ronald L.
    Hoffman, Lucas R.
    Kronman, Matthew P.
    Ong, Thida
    Rosenfeld, Margaret
    PEDIATRICS, 2017, 139 (02)
  • [7] Changes in Pediatric Health-Related Quality of Life in Cystic Fibrosis After IV Antibiotic Treatment for Pulmonary Exacerbations
    Modi, Avani C.
    Lim, Crystal S.
    Driscoll, Kimberly A.
    Piazza-Waggoner, Carrie
    Quittner, Alexandra L.
    Wooldridge, Jamie
    JOURNAL OF CLINICAL PSYCHOLOGY IN MEDICAL SETTINGS, 2010, 17 (01) : 49 - 55
  • [8] Home Intravenous Antibiotic Protocols for Acute Pulmonary Exacerbations in Patients With Cystic Fibrosis: A Scoping Review
    Odendaal, Michelle
    Tilbury, Zak
    Conway, Aaron
    HOME HEALTH CARE MANAGEMENT AND PRACTICE, 2025,
  • [9] Pulmonary Exacerbations in Cystic Fibrosis With Negative Bacterial Cultures
    Zemanick, Edith T.
    Wagner, Brandie D.
    Harris, J. Kirk
    Wagener, Jeffery S.
    Accurso, Frank J.
    Sagel, Scott D.
    PEDIATRIC PULMONOLOGY, 2010, 45 (06) : 569 - 577
  • [10] Outpatient management of pulmonary exacerbations in children with cystic fibrosis
    Perrem, Lucy
    Martin, Isaac
    Ratjen, Felix
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2023, 17 (04) : 295 - 304